These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17285459)

  • 21. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
    Whitacre CM; Zborowska E; Willson JK; Berger NA
    Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004.
    Price N
    Clin Prostate Cancer; 2004 Dec; 3(3):136-40. PubMed ID: 15636678
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase II inhibitors.
    Hande KR
    Cancer Chemother Biol Response Modif; 2003; 21():103-25. PubMed ID: 15338742
    [No Abstract]   [Full Text] [Related]  

  • 26. PARP inhibitors and cancer therapy - early results and potential applications.
    Jones C; Plummer ER
    Br J Radiol; 2008 Oct; 81 Spec No 1():S2-5. PubMed ID: 18819994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy Foundation Symposium XII. Innovative Cancer Chemotherapy for Tomorrow. New York City, November 9-11, 1994. Abstracts.
    Cancer Invest; 1995; 13 Suppl 1():1-59. PubMed ID: 7614145
    [No Abstract]   [Full Text] [Related]  

  • 28. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 29. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel poly(ADP-ribose) polymerase-1 inhibitors.
    Dunn D; Husten J; Ator MA; Chatterjee S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):222-4. PubMed ID: 22153339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy Foundation Symposium XV. Innovative Cancer Therapy for Tomorrow. New York City, New York, USA. November 12-14, 1997. Abstracts.
    Cancer Invest; 1998; 16 Suppl 1():1-85. PubMed ID: 9533009
    [No Abstract]   [Full Text] [Related]  

  • 33. Selected new developments in oncology.
    Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):140. PubMed ID: 20450478
    [No Abstract]   [Full Text] [Related]  

  • 34. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral cytotoxic drugs.
    Gridelli C; Rossi A; Guerriero C; Nicolella D; Ferrara C; Del Gaizo F; Colantuoni G; Airoma G; Maione P
    Suppl Tumori; 2002; 1(4):S19-23. PubMed ID: 12415809
    [No Abstract]   [Full Text] [Related]  

  • 36. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan: a new topoisomerase I inhibiting antineoplastic agent.
    Cersosimo RJ
    Ann Pharmacother; 1998 Dec; 32(12):1334-43. PubMed ID: 9876816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly(ADP-ribose) polymerase inhibitors.
    Garon EB; Dubinett SM
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S455-6. PubMed ID: 21102236
    [No Abstract]   [Full Text] [Related]  

  • 39. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.